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Abstract: 
The N-methyl-D-aspartate (NMDA) receptor, one of the ionotropic glutamate receptor, plays 
important physiological and pathological roles in learning and memory, neuronal 
development, acute and chronic neurological diseases and neurogenesis.  This work aimed to 
examine the contribution of the NR2B NMDA receptor subunit to adult neurogenesis/cell 
proliferation under physiological conditions and following an excitotoxic insult.  We have 
previously shown in vitro that a discrete NMDA-induced, excitotoxic injury to the 
hippocampus results in an increase in neurogenesis within the dentate gyrus.  Here we have 
characterised adult neurogenesis or proliferation, using BrdU, in an in vivo model of 
excitotoxic injury to the CA1 subfield of the hippocampus.  We demonstrate a peak in neural 
stem cell proliferation/neurogenesis between 6-9 days after the excitotoxic insult.  Treatment 
with ifenprodil, an NR2B subunit specific NMDA receptor antagonist, without prior injury 
induction, also increased the number of BrdU-positive cells within the DG and posterior 
periventricle, indicating that ifenprodil itself could modulate the rate of proliferation.  
Interestingly though, the increased level of cell proliferation did not change significantly 
when ifenprodil was administered following an excitotoxic insult.  In conclusion, our results 
suggest and add to growing evidence that NR2B-subunit containing NMDA receptors play a 
role in neural stem cell proliferation. 
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 Introduction:  
  
 In the mammalian brain, neurogenesis occurs throughout life (Altman and Das, 1965, 
Cameron and McKay, 2001). This neurogenic activity is centred on two regions of the adult 
brain: the subgranular zone (SGZ) of the hippocampal dentate gyrus (DG) and subventricular 
zone (SVZ) of the lateral ventricle (Doetsch et al., 1997, Seri et al., 2004). The neuronal 
progenitor cells in the SGZ migrate a short distance into the granule cell layer where they 
mature, extend axonal projections and integrate into local networks (Stanfield and Trice, 
1988, Altman and Bayer, 1990). A large number of cells are produced in the SGZ but the 
majority die as a result of apoptosis. However, once through this critical period, they 
demonstrate long-lasting integration with the granule cell layer network (Kempermann and 
Gage, 1999). 
  
 There are many factors with demonstrated regulatory influence on adult hippocampal 
neurogenesis.  These include particular growth factors such as epidermal growth factor and 
fibroblast growth factor-2 (Kuhn et al., 1997), and conditions, such as enriched environments 
(Kempermann et al., 1997) and physical activity (van Praag et al., 1999).  Another influence 
on hippocampal neurogenesis is glutamatergic neurotransmission, primarily mediated 
through the NMDA receptor (Gould et al., 1994, Cameron et al., 1995).  Despite extensive 
study of glutamatergic neurotransmission, the role of glutamate in adult neurogenesis is far 
from clear.  Some studies have shown that NMDA receptor blockade increases neurogenesis 
suggesting that glutamatergic input to the dentate gyrus is involved in suppression of 
neurogenesis (Gould et al., 1994, Cameron et al., 1995, Nacher et al., 2003).  However, work 
in ischaemia models and seizure models have shown that increased glutamate signalling 
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caused an increase in hippocampal neurogenesis and that NMDA receptor blockade resulted 
in a reduction of neuronal stem cell production (Parent et al., 1997, Bernabeu and Sharp, 
2000, Arvidsson et al., 2001).  While these effects seem contradictory, one explanation for 
this discrepancy may be that the resulting cell death, rather than glutamate receptors directly, 
stimulates neurogenesis.  However, it is also possible that different NMDA receptor subtypes 
produce different effects.   
  
 The majority of the studies, to date, examining the role of the NMDA receptor in 
neurogenesis, have used non-selective antagonists, such as MK-801, APV or memantine 
(Kluska et al., 2005, Poulsen et al., 2005, Maekawa et al., 2009). One study which examined 
the role of NR2B containing NMDA receptors in vitro, suggested that these receptors 
mediate both survival and death signalling within a single neuron (Martel et al., 2009).  It is 
of interest therefore to examine, in vivo, the role of the NMDA NR2B-subunit in the 
regulation of adult neurogenesis.   
  
 We have previously established an in vivo model of excitotoxic injury in the mouse 
(Concannon et al., 2008).  In this study we aimed to characterise in vivo the effect of a 
discrete excitotoxic injury in the hippocampal CA1 subfield on neurogenesis, and the long-
term survival of these cells in the dentate gyrus and the posterior periventricle as this has 
recently been shown to be a neurogenic zone (Chechneva et al., 2005).  Finally, using this 
model, the effects of the NMDA receptor NR2B subunit selective antagonist, ifenprodil, on 
proliferation and survival were evaluated.  
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 Materials and Methods: 
 
2.1 Animals:  
Male C57BL/6 mice (9-weeks old), obtained from Harlan UK Ltd., were housed 5 per cage, 
with food and water available ad libitum. A 12-hour light-dark cycle was maintained (light 
hours 07.00–19.00 h).  All animal experiments were carried out under licence from the 
Department of Health and Children (Ireland), in accordance with the European Communities 
Council Directive 86/609/EC and all procedures were approved by the Research Ethics 
Committee of the Royal College of Surgeons in Ireland.  All mice were 10-weeks old at the 
start of the experimental procedures. 
 
2.2 Surgery:  
The mice (n=6-9 per group) were anaesthetised by injection of ‘Avertin’ (i.p.) at a dose of 10 
ml/kg (Avertin concentrate consists of 100 g of 2,2,2-tri-bromoethanol dissolved in 62 ml of 
tert-amyl alcohol: 5 ml of this concentrate are added to 20 ml absolute alcohol and 250 ml of 
0.9% saline). The head was secured in a stereotaxic frame (Stoelting, USA) and an incision 
made in the scalp to expose the skull. If necessary, the position of the incisor bar was 
adjusted to ensure that bregma and lambda were in the same horizontal plane.  The body 
temperature of the mice was maintained at a normal level using a feedback controlled 
homeothermic blanket. 
 
A small hole was drilled to the right of the midline at the appropriate coordinates (anterior-
posterior = -1.9mm from Bregma; Medial-lateral = +1.5mm from the midline; dorsal-ventral 
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= -1.2 mm from brain surface; injection volume 0.05 µl).  An infusion of 10 mg/ml N-methyl 
D-aspartic acid (NMDA) solution [in phosphate buffered saline (PBS)] or vehicle was made. 
Injections were made using a 34-gauge stainless steel cannula (Cooper’s Needle Works, 
Birmingham, UK) mounted on a 5 µl microsyringe (Scientific Glass Engineering, Milton 
Keynes, UK). Each infusion was administered at a rate of 0.1 µl/min and the cannula 
remained in place for 1 minute following infusion to allow for diffusion into the surrounding 
tissue.  These injection coordinates and volume were chosen based on our previous work 
(Concannon et al., 2008) and preliminary studies to ensure only the CA1 subfield was 
affected and not the dentate gyrus. Finally, the scalp was sutured and the animals were 
closely monitored, in a temperature-controlled environment until recovery from the 
anaesthetic.   
 
2.3 BrdU Administration:  
In order to visualise dividing cells in the dentate gyrus, BrdU (5-bromo-2- deoxyuridine) was 
administered by intraperitoneal (i.p.) injection on days 6-9.  BrdU was prepared at 10 mg/ml 
(65 mM) in sterile saline (0.9 %) and injected i.p. at 5 ml/kg to achieve an effective dose of 
50 mg/kg as previously described (Gage et al., 1995)(Figure 1).   
 
2.4 Ifenprodil administration:   
Where appropriate to the experiment, ifenprodil (5 mg/kg, in 0.9% sterile saline (Sigma-
Aldrich, Ireland)) was administered by the i.p. route on days 4-9 following stereotaxic 
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surgery, to ensure the primary cell death processes had ceased and to cover the peak 
neurogenesis time (Figure 1C) 
 
2.5 Histology:  
After the appropriate survival times, animals were sacrificed by terminal anaesthesia with 
sodium pentobarbitone, (200 space mg/kg, i.p.) and transcardially perfused, at a rate of 4 
ml/min, with either 40 ml phosphate buffered saline (PBS) or 20 ml PBS followed by 20 ml 
of ice cold 4 % paraformaldehyde (PFA). Following perfusion, PBS treated brains were 
removed, snapfrozen in iso-pentane and stored at –80 °C.  PBS and 4 % PFA perfused brains 
were removed and post-fixed in 4 % PFA for 12 hours at 4 °C.  These brains were then 
transferred into 30 % sucrose/PBS until they were equilibrated and then frozen at –20 °C 
before being stored at –80 °C until further processing.   
 
In preparation for histology, the brains were sectioned, coronally, at 10 μm, using a cryostat 
(Leica, Germany).  Collection of the sections commenced at an anterior–posterior coordinate 
of -1.4mm (from Bregma according to the Mouse Brain in Stereotaxic Coordinates, Paxinos 
and Franklin (Paxinos, 2001)). Sets of four consecutive sections were collected every 40 µm 
up to an anterior–posterior coordinate of -2.4mm (from Bregma). 
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2.6 Tissue preparation:  
This was carried out using established protocols, published elsewhere (Bunk et al., 2010a) 
but described in brief here. 
 
2.6.1 BrdU labelling, BrdU/NeuN and BrdU/GFAP double-labelling:  
Brain slices were washed in PBS, DNA was denatured with 2 N HCl for 20 min at 37
o
C, and 
neutralised with 0.1M borax buffer (pH 9) for 20 min at room temperature. After a washing 
step, the tissue was incubated with 10% fetal calf serum for 1 h at room temperature. Primary 
antibodies (rat anti-BrdU, AbD Serotec, UK, 1/300; mouse anti-NeuN, Chemicon, Ireland, 
1/500 or mouse anti-BrdU, BD Bioscience, UK, 1/100; rabbit anti-GFAP, 1/500, Sigma-
Aldrich, Ireland) were diluted in blocking solution and applied overnight at 4 
o
C. After 
washing, the respective secondary antibodies were applied for 2 h at room temperature. 
 
 
2.6.2 Doublecortin labelling:   
Brain slices were washed in PBS before incubation with 0.1% Triton X-100/PBS for 15 min 
on ice. After washing in PBS, slices were blocked in 5% horse serum and 0.3% Triton X-
100/PBS for 30 min at room temperature. After further washing in PBS, goat anti-DCX 
antibody (Santz Cruz, 1/100, Santa Cruz Biotech, Heidelberg, Germany) was applied in 
blocking solution overnight at 4
o
C. After washing the secondary antibody, donkey-anti-goat 
rhodamine conjugated (Jackson Immunoresearch, Plymouth, PA, USA, 1/1000) was applied 
for 2 h at room temperature.   
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2.6.3 BrdU and doublecortin double-labelling:  
For this step, a combination of the protocols described above was used. First, brain slices 
were stained for DCX using goat anti-DCX and donkey-anti-goat fluorescein conjugated. 
Following washing, slices were then prepared for BrdU labelling and mouse anti-BrdU (BD 
Bioscience, 1/100) was used as primary antibody and goat anti-mouse 568 (Molecular 
probes, 1/1000) was used as secondary antibody.  Slices were embedded in DAPI-containing 
mounting media or incubated with Hoechst 33342, and then washed and mounted in 
FluorSave Reagent (Calbiochem, Merck Bioscience, Nottingham, UK).  Control experiments 
were performed by incubation with secondary antibodies only and no unspecific staining was 
observed.   
 
2.6.4 TUNEL staining:  
To analyse apoptotic cell death, specifically nuclear DNA fragmentation, brain sections were 
labelled using the DeadEnd™ Fluorimetric TUNEL System (Promega).  Briefly, after 
washing in PBS, the brain sections were permeabilised in 3 % Triton X-100 / PBS for 20 
min, again washed with 0.1 % Triton X-100 / PBS and incubated with equilibration buffer for 
15 min at room temperature. After equilibration the TUNEL solution containing 90μl 
equilibration buffer, 5 µl nucleotide mix and 1 µl rTdT (terminal deoxynucleotidyl 
transferase) per microscope slide was applied to the slices for 90 min at 37 °C. The enzymatic 
reaction was terminated with 2 x SSC (sodium chloride-sodium citrate buffer) for 15 min at 
room temperature. The slices were washed 3 x 5 min in 0.1 % Triton X-100 / PBS, 2 x 5 min 
in PBS and 1 x 5 min in dH2O and mounted with DAPI containing medium. 
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2.7 Data quantification and statistical analysis:  
Cell counting was performed using an Eclipse TE 300 inverted microscope (Nikon) and a 
40x oil objective. BrdU, DCX, or TUNEL-positive cells or cells double positive for BrdU 
and DCX or NeuN were counted in the DG of the hippocampus. Only cells located within the 
SGZ and the GCL were included; cells without direct contact to the DG (located within the 
hilus) were excluded from counting. All counts were performed in a blinded manner and data 
are given as mean±S.E.M per 10 µm coronal section. Additionally, cell counts within the 
posterior periventricle were performed. This area was defined as a two to three cell layer-
comprising structure along the hippocampal cornu ammonis and leading into the lateral 
ventricle. Data were tested for normal distribution using the Shapiro-Wilk test of normality. 
Statistical significance of differences between means was evaluated, with SPSS version 15 & 
18, using different statistical tests depending on the situation and the parameters being 
evaluated.  The tests utilised were, for parametric data, the student’s t-test, one-way ANOVA 
and post hoc Tukey’s test or two-way ANOVA with post hoc Newman Keuls.  For non-
parametric data the Mann–Whitney U-test with a Bonferroni correction was used.   
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Results: 
 
3.1 Cell proliferation peaks in the DG, CA1 and pPV 6-9 days after NMDA-induced CA1 
injury:  We used an in vivo model of discrete excitotoxic injury to the CA1-region of the 
hippocampus and determined neurogenesis up to 65-days following the lesion (Figure 1). As 
can be seen in Figure 2 A&B, stereotaxic administration of NMDA into the hippocampus 
produced a selective excitotoxic lesion to the CA1 hippocampal subfield (Concannon et al., 
2008).  In contrast, injection of saline produced no detectable hippocampal injury (Figure 
2A).   
 
It is well established that proliferation is frequently increased after injury to the brain. To 
examine if this proliferation was up-regulated following NMDA-induced excitotoxcity, 
animals received daily BrdU injections (50 mg/kg, ip) at different time points following 
intrahippocampal NMDA or saline administration (day 0 – 3, 6 – 9 or 12 – 15). The animals 
were sacrificed 24 hours after the last BrdU injection and the brains examined.  BrdU-
positive cell counts within the DG and the posterior periventricle (pPV) revealed that 
proliferation was significantly up-regulated at 6 – 9 days following a discrete lesion of the 
hippocampus (DG, control 16.9 ± 2.7 vs. NMDA 32.2 ± 3.3 p < 0.05; pPV, control 18.2 ± 
2.4 vs. NMDA 28.5 ± 3.2 p < 0.05; values represent numbers of BrdU-positive cells/10 μm 
brain section ± standard error of the mean; control groups: n = 4 animals; NMDA treatment 
groups: n = 6 – 11 animals). Interestingly, while BrdU-positive cells were absent in the CA1 
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subfield of control animals, their number significantly increased within the CA1 subfield of 
NMDA injected animals at all time-points analysed (Figure 2C).  It can be concluded 
therefore that inducing injury to the CA1 subfield of the hippocampus results in increased 
proliferation within the DG (and also in CA1 and pPV) which is significant at days 6 – 9 
following injury. Subsequently, BrdU treatment was performed at this time point for all 
following experiments. 
 
In order to determine the phenotypic origin of the BrdU-positive cells co-staining with the 
astrocytic marker glial fibrillary acidic protein (GFAP), the neuronal progenitor marker, 
doublecortin (DCX) and the neuronal marker Neuronal Nuclei (NeuN) was performed.  
NeuN expression commences in early post-mitotic stages of immature neurons and remains 
within fully differentiated cells.  GFAP-positive cells within the DG not only account for 
astrocytes but also for radial glia-like stem cells (type I cells) (Steiner et al., 2004).  BrdU 
administration 6 – 9 days after NMDA-induced injury and analysis 24 hours after the last 
BrdU injection revealed that BrdU-positive cells were present in the SGZ of the DG (Figure 
2D). Additionally, GFAP-positive cells were located in and near the SGZ (Figure 2E).  
However, the staining did not overlap with BrdU, indicating that BrdU-positive cells did not 
have properties of astrocytes or radial glia-like cells. Additionally, it was observed that GFAP 
staining was increased at the site of injury, indicating the activation of astrocytes in response 
to excitotoxicity.  DCX-positive cells were located along the SGZ of the DG and BrdU-
positive cells, located within the pool of DCX-positive progenitor cells, also expressed DCX, 
indicating a neuronal progenitor phenotype of the newly generated cells (Figure 2F) and 
thereby demonstrating increased proliferation.  While mature neurons of the GCL expressed 
NeuN, the majority of BrdU-positive cells were negative for NeuN expression, indicating that 
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the newly generated cells had not yet matured into neurons.  Interestingly, in the NMDA 
treated mice, 13% of the BrdU positive cells already expressed NeuN, 24 hours after 4 days 
of BrdU injection, indicating that some cells had matured into neurons over this time period 
(Figure 3 A&B). 
 
Several earlier studies have proposed that BrdU can not only be incorporated into the DNA of 
dividing cells but also during DNA repair mechanisms of dying cells (Kuan et al., 2004). 
However, recent evidence suggests that this is rarely the case (Bauer and Patterson, 2005, 
Czaja et al., 2008). Therefore, to test whether this was the case here, the brain sections were 
stained for the apoptotic marker TUNEL (terminal deoxynucleotidyl transferase mediated 
dUTP nick end labelling) and for BrdU by immunohistochemistry.  As expected, BrdU-
positive cells were present in the SGZ of the DG as well as in the CA1 subfield.  However, 
only low levels of TUNEL-positive cells were observed in the CA1 subfield.  More 
importantly, there was no co-localisation of the two markers in the DG, indicating that BrdU 
was not taken up by apoptotic cells (Figure 2G). 
 
3.2 Long-term survival of newly-generated cells: 
While there is clearly an upregulation in neurogenesis following excitotoxic injury, it has 
been demonstrated that the majority of newly generated cell do not survive, with apoptotic 
cell death accounting for the fate of 60 – 80 % of the cells (Biebl et al., 2000). To examine 
the long term survival of the newly generated cells in this experimental model, BrdU was 
administered from days 6-9 following NMDA administration and the animals allowed to 
survive 24 hours, 28 days or 56 days after the last BrdU injection.  Other cell proliferation 
markers (for example Ki67, pH3) are effective indicators of cell proliferation, but are not 
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always applicable for tracking the cell fate (Kee et al., 2002).  As expected and seen above, 
twenty-four hours after the last BrdU injection the number of BrdU-positive cells was 
significantly up-regulated in all areas analysed.  However, after longer survival periods of 28 
or 56 days the number of cells was greatly reduced in DG, CA1 and pPV, indicating that the 
newly generated cells did not survive longterm (Figure 4). Importantly, there was no 
difference between control animals and those that received intrahippocampal NMDA 
injections, indicating that even the increased number of cells generated following 
excitotoxicity could not survive. 
 
It was of interest to assess the phenotypic fate of the cells that survived for 28 or 56 days.  
Co-staining for BrdU and the neuronal marker NeuN was performed.  After 28 days (Figure 5 
(A&B)) and 56 days (Figure 5 (C&D)), the majority of BrdU-positive cells were positive for 
the mature neuronal marker NeuN in both control and NMDA-treated animals.  Survival of 
the animals for 28 or 56 days following the last BrdU injection resulted in maturation of 70 – 
83 % of the BrdU-positive cells into a neuronal phenotype.  However, there was no 
difference between NMDA treated and control animals (28 days: control (70%) vs NMDA 
(83%), p>0.05; 56 days: control (80%) vs NMDA (72%), p>0.05). 
 
3.3 Ifenprodil increases adult neurogenesis/cell proliferation in the dentate gyrus: 
To examine the role of NMDA receptor modulation on neurogenesis, the polyamine/NR2B 
antagonist, ifenprodil, was assessed.  In addition to the administration of BrdU following 
intrahippocampal NMDA, the animals received intraperitoneal injections of ifenprodil on 
days 4-9 following NMDA-induced excitotoxicity. In order to analyse the effect of ifenprodil 
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on injury-induced proliferation, one group of animals was sacrificed 24 hours after the last 
BrdU and ifenprodil injection.  
 
As expected from the earlier experiments, in the animals sacrificed 24 hours after BrdU 
administration, there was a significant increase in the number of BrdU-positive cells in the 
DG of NMDA injected mice (F1,21= 5.855, p<0.05; Figure 6A).  There was also a significant 
effect of ifenprodil treatment (F1,21= 6.008, p<0.05), though there was no interaction (F1,21= 
1.627, p>0.05).  Interestingly, in control animals that did not receive NMDA, but were 
treated with ifenprodil, proliferation was similarly increased (saline/ifenprodil 18.9 ± 2.3 (n = 
8), p < 0.05 vs saline/saline group).  Additionally, an increase was also observed when 
animals received NMDA and subsequently ifenprodil 4 – 9 days afterwards 
(NMDA/ifenprodil 21.5 ± 1.7 (n = 10 animals), with p < 0.01 versus control saline/saline 
group). However, the increase in BrdU-positive cells within the NMDA/ifenprodil animals 
was similar compared to NMDA/saline or saline/ifenprodil animals. 
 
In the pPV the effect of NMDA was significant (F1,23= 11.783, p<0.01), meaning NMDA 
injection resulted in an increase in BrdU-positive cells.  However, the effect of ifenprodil did 
not reach statistical significance, though there was a trend towards increased BrdU-positive 
cells (Figure 6B). However, NMDA-induced excitotoxicity alone (NMDA/saline) or together 
with ifenprodil (NMDA/ifenprodil) resulted in an increase of BrdU-positive cells within the 
pPV 24 hours after the last BrdU and ifenprodil injection (pPV (24 h), saline/saline 19.5 ± 
3.3 (n = 6) vs. NMDA/saline 39.6 ± 3.7 (n = 10 animals), p < 0.01 and vs. NMDA/ifenprodil 
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35.9 ± 3.3 (n = 10) , p < 0.01, values represent numbers of BrdU-positive cells/10 μm brain 
section).  In addition, there was no difference between the NMDA/ifenprodil and 
NMDA/saline groups. 
 
Finally we were interested in studying the long-term survival of newly-generated cells 28 or 
56 days after the last BrdU injection.  Only a small number of newly generated cells 
remained within the DG and there was no difference in cell numbers between the different 
treatment groups, suggesting that the administration of ifenprodil during the period of 
neurogenesis had no influence on long-term survival of the newly generated cells.  However, 
phenotypic analysis, through double staining with NeuN, showed that 70-83% of the 
surviving cells in the DG displayed a neuronal phenotype. 
 
In the pPV, BrdU-positive cells were still significantly elevated 28 days following BrdU  
and ifenprodil treatment in NMDA-injected mice, suggesting that these cells had survived 
longer compared to control (pPV (28 d), saline/saline 3.5 ± 1.1 (n = 6) vs. NMDA/ifenprodil 
10.4 ± 2.3 (n = 10), p < 0.05).  In the NMDA/saline group there was a trend towards 
increased BrdU positive cells, though this did not reach significance (p=0.08).  However, 
after 56 days survival there was a further decrease in the number of BrdU positive cells and 
only cells within the NMDA/Saline group were significantly increased compared to controls 
(pPV (56 d), saline/saline 2.5 ± 0.6 (n = 6) vs. NMDA/saline 5.7 ± 1.2 (n = 10), p < 0.05).   
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In addition, the effect of ifenprodil on the number of BrdU-positive cells within the CA1 
subfield after NMDA-induced excitotoxicity was examined. Similar to the results from the 
model characterisation (Figure 4B), control animals which had not received NMDA 
treatment (saline/saline) did not display BrdU-positive cells in the hippocampal CA1 subfield 
at any time point analysed.  Likewise, control animals, receiving intraperitoneal ifenprodil 
injections (saline/ifenprodil), did not show BrdU-positive cells within the CA1.  Both the 
saline/ifenprodil and the saline/saline groups showed an average of <1 BrdU positive cell per 
10 µm section at the three time points.  This suggested that ifenprodil alone had no effect on 
the number of BrdU-positive cells in this area, in contrast to the observed effect within the 
DG and pPV.  
 
Survival for 28 days resulted in similar numbers of BrdU-positive cells within the 
NMDA/Saline and NMDA/ifenprodil treatment groups when compared to each other 
(NMDA/saline vs NMDA/ifenprodil; 11.9±5.2 vs 13.9±9 cells/10 µm section, p>0.8). BrdU-
positive cells were almost completely absent in the CA1 subfield after survival of the animals 
for 56 days. 
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4. Discussion: 
 
Injury to the brain, for example cerebral ischemia, status epilepticus or traumatic brain injury 
results in the excessive release of glutamate and over-activity of glutamatergic receptors 
producing apoptotic and necrotic cell death in the affected areas (Choi, 1994, Henshall, 2007, 
Besancon et al., 2008).  However, these types of injuries also result in increased neurogenesis 
within the SGZ of the hippocampal dentate gyrus (Parent et al., 1997, Arvidsson et al., 2001).  
The aim of this study was to further characterise adult neurogenesis/cell proliferation in an in 
vivo model of NMDA-induced excitotoxicity, specifically targeting the hippocampal CA1, 
which is known to be susceptible to excitotoxic injury and selectively vulnerable in models of 
global cerebral ischaemia (Kirby and Shaw, 2004, Zhang and Chen, 2008). In addition, the 
influence of the NMDA receptor subunit, NR2B, was examined in these processes, through 
the use of the competitive antagonist to NR2B-subunit containing receptor complexes, 
ifenprodil (Williams, 2001). Our study shows that there is up-regulation of proliferation in 
the dentate gyrus and the posterior periventricle following the excitotoxic insult and that the 
peak of proliferation (represented by BrdU incorporation) occurs approximately 6 - 9 days 
after the insult.  This is in line with previous in vitro work from our lab using organotypic 
hippocampal cultures that also showed increased proliferation 6 - 9 days after NMDA 
exposure (Bunk et al., 2010b). Furthermore, our result is in agreement with other literature, 
which shows there is a latent period between occurrence of the injury and subsequent 
increase in proliferation (Parent et al., 1997, Takagi et al., 1999).  Takagi et al. (1999) 
demonstrated an up-regulation of neurogenesis 4 – 9 days after transient forebrain ischemia, 
which was significantly decreased thereafter (14 – 16 days).  Parent et al. (1997) showed up-
regulation of neurogenesis for a more prolonged period of up to 13 days following status 
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epilepticus. However, the likelihood is that different insults to the brain induce proliferation 
within slightly altered timeframes. 
 
As other groups have previously demonstrated, the cell proliferation was confirmed using  
double-labelling with BrdU and the immature neuronal marker, DCx (Rao et al., 2008).  DCx 
expression has been shown to occur very soon after cell birth in neuronally destined cells 
(Kempermann et al., 2003).  The phenotypic fate of the neural stem cells was also examined 
through the use of double labelling with BrdU and the early post-mitotic neuronal marker, 
NeuN.  Expression of NeuN commences as early as 1 or 2 days following the last cell 
division and subsequently BrdU/NeuN-positive cells can be detected one day following a 
single BrdU injection (Brandt et al., 2003). Indeed, 24 hours after the last BrdU injection 
some BrdU-positive cells were found to express NeuN indicating that those cells had left the 
cell cycle and developed a neuronal phenotype. In addition, co-labelling for GFAP was 
carried out to determine the effect on the two types of GFAP expressing cells in the dentate 
gyrus, namely radial glia-like stem cells and horizontal astrocytes (Steiner et al., 2004).  
However, the excitotoxic insult did not result in increase in BrdU/GFAP-positive co-labelling 
in the dentate gyrus, nor was there an increase in GFAP expression alone in the dentate 
gyrus.  Coupled with the lack of BrdU labelling of horizontal astrocytes, this suggests that 
gliosis did not play a major role in the dentate gyrus in this injury model.  This is in line with 
previous work by Tureyen and co-workers who showed that middle cerebral artery occlusion 
induced up-regulated BrdU incorporation into DG cells, but 21 days following injury those 
cells had developed into neurons, while no BrdU cells were found positive for GFAP 
(Tureyen et al., 2004). 
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There is some debate as to whether BrdU could be incorporated into dying cells during DNA 
repair mechanisms (Kuan et al., 2004), though there is evidence to suggest that this is not 
actually the case (Palmer et al., 2000, Bauer and Patterson, 2005, Czaja et al., 2008). In our 
study, no co-staining of the two markers was observed either in the DG or in the hippocampal 
CA1 subfield, strongly suggesting that BrdU incorporation was not a result of repair 
mechanisms of dying cells, but rather due to DNA replication during cell division.  
 
It is well established from ischaemia models and kainic acid induced damage, that damage to 
the CA1 results in increased proliferation in the DG (Arvidsson et al., 2001, Wang et al., 
2005).  Furthermore, work has also demonstrated re-population of cells in the CA1 following 
an ischaemic insult, with the origin of these cells being the posterior periventricle 
(pPV)(Nakatomi et al., 2002).  Similarly, Bendel and co-workers showed regeneration of 
cells in the CA1 following an ischaemic insult, in line with restoration of cognitive function, 
with the origin of the cells likely to be the periventricular region (Bendel et al., 2005).  
Through similar experimental means, research has shown the important role of these newly 
generated cells in learning and memory.  If there is a reduction in neurogenesis, through 
drug-induced ablation of neurogenesis, impairment in pattern recognition has been seen  
(Clelland et al., 2009).  Similarly, other hippocampal dependent tasks and long term spatial 
memory are impaired if there is a reduction in neurogenesis (Shors et al., 2001, Deng et al., 
2009, Jessberger et al., 2009).  These studies were more concerned with increased 
proliferation in the DG, but the work by Nakatomi et al looked at the pPV (Nakatomi et al., 
2002).  Further work has shown that the pPV generated progenitors have the ability to 
migrate to the peri-injured cortex following traumatic brain injury (Yi et al., 2013).  Even 
with this evidence, there is still debate as to the functional and clinical importance of 
neurogenesis and hippocampal (or pPV) generated progenitor cells. 
21 
Furthermore, despite significant research effort, the exact signalling mechanism behind these 
effects is still to be fully elucidated.  However, there is some evidence to implicate different 
growth factors in the neurogenesis.  Nakatomi et al demonstrated a role for epidermal growth 
factor and fibroblast growth factor-2 (Nakatomi et al., 2002) and Activin A, a member of the 
transforming growth factor-β superfamily (Abdipranoto-Cowley et al., 2009).  While the 
experimental protocols are different between these studies and ours, it is reasonable to 
suggest that they may have a role in the increased proliferation seen in our study. 
 
Following long-term survival, there was a marked decrease in the number of BrdU positive 
cells.  However, based on the literature, this was to be expected as other groups have seen 
this, albeit in naïve animals (Kempermann et al., 1997, Dayer et al., 2003).  Two main 
reasons have been proposed for this decrease in numbers over time; dilution of BrdU to 
undetectable levels through cell division (Hayes and Nowakowski, 2002) and death of the 
newly generated cells (Biebl et al., 2000).  It is thought that cell death accounts for the 
majority of this decrease as it has been suggested that while neurogenic regions show 
increased cell proliferation, they also have higher rates of cell death (Biebl et al., 2000).  The 
death of the newly generated cells seems to cease at approximately 4 weeks and this is the 
time that corresponds to the development of mature neuronal features (Dayer et al., 2003).  
This is mirrored in our study which shows a large decrease in BrdU positive cells up to 
28days, but the decrease from 28 to 56 days survival is only modest.  The death of these 
newly generated cells is most likely through programmed cell death/apoptosis (Biebl et al., 
2000).  The likelihood is that the pro- and anti-apoptotic Bcl-2 protein family play an 
important role in this as it has been demonstrated that Bcl-2 expression is retained in 
neurogenic regions of the adult brain and that Bcl-2 overexpression reduces death of 
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adult/newly-generated cells (Merry et al., 1994, Kuhn et al., 2005).  Furthermore, it has been 
demonstrated that knock-out of the pro-apoptotic protein Bax (Sun et al., 2004) or the pro-
apoptotic BH3-only proteins BIM and PUMA (Bunk et al., 2010a) significantly reduces 
apoptosis in the dentate gyrus.   
 
Of these surviving BrdU-positive cells, the majority expressed a neuronal phenotype. 
Following 28 or 56 days survival between 70 and 83 % of the remaining BrdU-positive cells 
showed NeuN expression and there was no difference between control and NMDA treated.  
This result is consistent with other studies on naïve animals (Biebl et al., 2000, Brandt et al., 
2003, Dayer et al., 2003) as well as after brain injury such as transient forebrain ischemia 
(Kawai et al., 2004), demonstrating that the majority of newly generated cells develops a 
neuronal phenotype within the DG.  In addition, the work by Nakatomi et al showed that 
newly re-generated pyramidal cells in the CA1 became integrated in the hippocampal 
circuitry for at least the period of their study (6 months) and similarly the work by Bendel et 
al demonstrated that the newly regenerated cells expressed a mature neuronal phenotype and 
indicated by NeuN staining (Nakatomi et al., 2002, Bendel et al., 2005). 
 
It is well established that the NMDA receptor has a role in the regulation of adult 
neurogenesis; however, it is not clear if this is a facilitatory or inhibitory role (Cameron et al., 
1995, Arvidsson et al., 2001, Nacher et al., 2003).  Ifenprodil was used to antagonise NR2B-
subunit containing NMDA receptor activity following an excitotoxic insult and determine the 
effect on neurogenesis.   
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In our study, it was demonstrated that following ifenprodil administration, proliferation was 
significantly increased in the dentate gyrus not only after NMDA treatment but also in 
control animals that had received ifenprodil alone.  As ifenprodil alone is unlikely to cause 
cell death, this result shows that the effect seen is due to ifenprodil, particularly as this is also 
seen in areas not strongly or directly affected by the cell death.  This finding suggests that 
reduction of NR1/NR2B NMDA receptor activity (Amico-Ruvio et al., 2012), through 
ifenprodil treatment, can promote neuronal precursor cell proliferation. While the result for 
the control and ifenprodil treated animals did not reach statistical significance in the pPV, 
there was a trend showing an increase in BrdU
+
 labelling.  In addition, the increase in 
proliferation that we have seen, cannot be simply linked to cells undergoing cell death as we 
would have therefore seen a decrease rather than increase in BrdU+ labelling when 
comparing the NMDA and NMDA/ifenprodil groups (Mishra et al., 2011).  Of note, 
ifenprodil has been shown to exert effects through other receptor systems, such as the 5-HT3 
receptors (McCool and Lovinger, 1995), sodium channels (Tanahashi et al., 2007), calcium 
channels (Bath et al., 1996) and the Na
+
/Ca
2+
 exchanger (Brittain et al., 2012). 
 
However, our results are in agreement with a recent study which showed that only the 
selective NR2B blocker Ro 25-6981, and not the non-subunit selective open channel blocker 
MK-801, could increase neuronal stem cell proliferation in vitro (Hu et al., 2008).  Given that 
a certain level of NMDA receptor activity is essential for cell survival (Hwang et al., 1999), it 
could be that blocking the NR2B containing NMDA receptors, and leaving the activity of 
NR2A containing receptors unaffected, enhanced NR2A-dependent signal transduction was 
responsible for the increase in cell proliferation in the dentate gyrus, though this would need 
to be studied further. 
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Ro 25-6981 has been shown to inhibit the downstream enzymatic activity of neuronal nitric 
oxide synthase (nNOS) through an action on the NMDA receptor (Hu et al., 2008).  
Therefore, one possible explanation is that neuronal precursor cell proliferation is regulated 
in a negative manner via the NR2B subunit of the NMDA receptor, for example by regulating 
downstream activation of nNOS.  However, MK-801 will also inhibit nNOS and yet Hu and 
colleagues did not see an increase in proliferation from MK-801 treatment.  This suggests 
that the mechanisms of neurogenesis need to be further examined, particularly as recent work 
showed that the source of NO has a differential effect on neurogenesis, either stimulation or 
inhibition (Luo et al., 2010).  In addition, ifenprodil interacts in a negative allosteric manner 
with the polyamine binding site on the NMDA receptor (Reynolds and Miller, 1989, Han et 
al., 2008), and since the polyamines may have a role in neural stem cell proliferation and 
differentiation (Cohen, 1998), this may further contribute to an effect of ifenprodil on 
neurogenesis. 
 
Our study has shown that in the long-term survival groups, following ifenprodil 
administration, there was no difference in the ability of the cells to survive between the 
different treatment groups, in both the DG and the proposed neurogenic area, pPV.  However, 
ifenprodil was administered only for a relatively short period of time (4 – 9 days following 
NMDA-induced injury) and it is possible that for ifenprodil to have an effect it would need to 
be administered at different time points throughout the survival period.  Therefore, one 
cannot exclude an effect of ifenprodil on cell survival.  However, a study by Chen et al. 
(2007) showed that expression of BDNF, which was shown to be involved in survival of 
newly generated cells, was independent of NR2B/NMDA receptor inactivation by ifenprodil, 
but was induced by NR2A/NMDA receptor activity (Chen et al., 2007).  
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This study has provided further evidence that administration of NMDA to the CA1 subfield 
of the hippocampus can produce a discrete lesion that results an increase in proliferation in 
the dentate gyrus and posterior periventricle, thus allowing this process and the long-term 
survival of the newly-generated cells to be studied.  Using this model it was shown that 
ifenprodil increased precursor cell proliferation even under control conditions.  While further 
molecular mechanistic studies are needed to fully define the role of the NMDA receptors, this 
work suggests that NR2B/NMDA receptors may fulfil a negative regulatory role during this 
process of neurogenesis.  
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Figure Legends: 
 
Figure 1: 
Diagrammatic representation of the experimental protocols used in this study 
A: Summary of the experimental set-up to assess the peak time point of neurogenesis after 
NMDA-induced excitotoxic cell death. Animals received intrahippocampal NMDA or saline 
at day zero. BrdU was administered i.p. at different time points (days 0 – 3, 6 – 9 or 12 – 15) 
followed by transcardial perfusion 24 hours after the last BrdU injection.   
B: Summary of the experimental set-up for analysis of long-term survival of newly generated 
cells after NMDA-induced excitotoxicity. Mice received intrahippocampal NMDA injections 
at day zero, i.p. injections of BrdU at days 6 – 9 and were sacrificed by transcardial perfusion 
24 hours, 28 days or 56 days after the last BrdU injection.    
C: Summary of the experimental set-up for analysis of the effect of ifenprodil on 
neurogenesis and survival of cells newly generated after NMDA-induced excitotoxicity. The 
same set-up as described in B above was used. Additionally, animals received Ifenprodil or 
vehicle solution at days 4 – 9 after intrahippocampal NMDA injection.      
 
 
Figure 2: 
Discrete NMDA-induced injury to the CA1 subfield of the hippocampus.   
NMDA (10 mg/ml) was administered to the hippocampus and induced cell death localised to 
the CA1 region (A, A’ – control; B, B’ – NMDA-induced excitotoxic injury) and indicated 
by the arrows (hematoxylin stain). Scale bar = 500 µm (A & A’); 100 µm (B & B’) C: 
Quantification of BrdU-positive cells (cell proliferation) in DG, CA1 subfield and pPV after 
NMDA-induced excitotoxicity. Following NMDA administration, animals were treated with 
daily BrdU (ip) injections at 0 – 3 (control: n = 4; NMDA treatment: n = 8 animals), 6 – 9 
(control: n = 4; NMDA treatment: n = 11 animals) and 12 – 15 (control: n = 4; NMDA 
treatment: n = 6 animals) days after NMDA treatment.  Transcardial perfusion occurred 24 
hours after the last BrdU injection. BrdU-positive cells were counted in the DG, CA1 
subfield and pPV and numbers were compared between NMDA treated and control animals.  
The peak time for BrdU-positive cells was 6-9 days after NMDA injury.  DAI, days after 
injury; DG, dentate gyrus; CA1, cornu ammonis; pPV, posterior periventricle. Error bars 
represent SEM. * p < 0.05.  
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D: Illustration of BrdU+ cells in the dentate gyrus, the hippocampal CA1 and the posterior 
periventricle.  Scale bar = 50 µm (DG); 25 µm (CA1 & pPV)  E: GFAP-positive cells in DG 
and CA1 after NMDA-induced injury in the CA1 subfield. BrdU-positive cells (green) were 
present in the SGZ of the DG, indicating the generation of new cells (open arrowheads). 
GFAP-positive cells (red) were also found in SGZ and GCL, but staining did not co-localise 
with BrdU (closed arrowheads). BrdU-positive cells in the CA1 subfield were found at the 
site of injury. Some BrdU-positive cells stained positive for GFAP (closed arrowheads) 
whereas others did not (open arrowheads). DG, dentate gyrus; GCL, granule cell layer; SGZ, 
subgranular zone; CA1, cornu ammonis. Scale bar = 50 µm (DG); 25 µm (CA1)  F: 
Doublecortin expression in BrdU-incorporated cells of the DG. The marker DCX is evident 
as a red marker and occasional co-localisation with BrdU-positive cells was seen 
(arrowhead). GCL, granule cell layer; SGZ, subgranular zone; DG, dentate gyrus; DCX, 
doublecortin. Scale bar = 50 µm  G: BrdU positivity was not associated with apoptotic cell 
death. BrdU-positive cells (red/purple) were present in the SGZ of the DG indicating the 
generation of new cell. TUNEL-positive cells (green) were found in the DG, but the staining 
showed no co-localisation with BrdU. BrdU-positive cells appeared in the injured area of the 
CA1 subfield but again TUNEL staining showed no co-localisation with BrdU. DG, dentate 
gyrus; GCL, granule cell layer; SGZ, subgranular zone; CA1, cornu ammonis.  Scale bar = 50 
µm 
 
Figure 3: 
BrdU and NeuN staining in the dentate gyrus in mice sacrificed 24 hours after treatment. 
A Quantification of BrdU+/NeuN- and BrdU+/NeuN+ cells within the Dentate Gyrus 
revealed that 24 hours following the last BrdU injection 13 % (NMDA) – 15 % (control) of 
the BrdU-positive cells were already positive for NeuN. The total number of BrdU-positive 
cells was significantly increased in the NMDA treated animals compared to control. Control: 
n = 6, NMDA treatment: n = 10. Error bars represent the standard error of the mean. * p < 
0.05 v control.  B After 4 days of BrdU treatment, a small proportion of BrdU-positive cells 
were also NeuN-positive (arrow).  Scale bar = 10 µm 
 
Figure 4: 
Long term survival of BrdU-positive cells in DG, CA1 subfield and pPV after NMDA-
induced excitotoxic cell death in the CA1 subfield. Animals were subjected to NMDA 
administration and subsequent BrdU injections 6 – 9 days after NMDA and transcardial 
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perfusion 24 hours, 28 days or 56 days after the last BrdU injection (see Figure 1 for 
illustration). BrdU-positive cells were counted in DG (A), CA1 (B) subfield and pPV (C) and 
cell numbers were compared between NMDA treated and control animals at each survival 
time point. BrdU-positive cells were significantly up-regulated after NMDA treatment 
compared to control animals 24 hours after the last BrdU injection in all hippocampal 
subfields analysed. At 28 or 56 days after the last BrdU injection there was no difference 
between NMDA treatment and control animals. Control: n = 6, NMDA treatment: n = 10 for 
all survival groups. Error bars represent the standard error of the mean. * p < 0.05 v 
control/saline. 
 
 
Figure 5: 
NeuN-positive cells in the DG after NMDA-induced injury in the CA1 subfield following 
different survival periods. Animals were subjected to NMDA administration and subsequent 
BrdU injections 6 – 9 days after NMDA and transcardial perfusion 28 days or 56 days after 
the last BrdU injection.  After 28 (A-B) and 56 (C-D) days BrdU-positive cells were also 
positive for the mature neuronal marker NeuN in control (A, C) and NMDA treated (B, D) 
animals. Arrows within each panel point at the same cells. Scale bar 50 μm. Columns shown 
represent a merged picture, DAPI stain, BrdU stain and NeuN stain.  GCL, granule cell layer. 
 
 
Figure 6: 
Effect of Ifenprodil on proliferation in DG and pPV after NMDA-induced excitotoxicity. 
Animals were subjected to intrahippocampal NMDA administration followed by i.p. BrdU 
injection at day 6 – 9 post NMDA treatment. Animals received 5 mg/kg (ip) Ifenprodil or 
saline on days 4 – 9 following NMDA. At 24 hours, 28 or 56 days after the last BrdU and 
Ifenprodil/saline injection animals were sacrificed by transcardial perfusion and brains were 
assessed for BrdU incorporation in the DG and pPV. (A) 24 hours after the last BrdU 
injection BrdU-positive cells increased significantly in the DG of NMDA treated animals 
(dark grey bar), Ifenprodil injected animals (light grey bar) and animals treated with both 
NMDA and ifenprodil when compared to control. At 28 or 56 days after the last BrdU 
injection only few cells remained and there was no difference between the different treatment 
groups (A). (B) In the pPV BrdU-positive cells were significantly increased in NMDA and 
NMDA/ifenprodil treated animals compared to control (white bar) 24 hours after the last 
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BrdU injection. Ifenprodil treatment alone resulted in increased BrdU-positive cell numbers 
compared to control animals though this did not reach significance in the pPV (p = 0.1). At 
28 and 56 days after the last BrdU injection NMDA/Saline or NMDA/Ifenprodil treatment 
resulted in an increase of BrdU-positive cell survival at 28 days in the NMDA/Ifenprodil 
group and at 56 days in the NDMA/saline group, though the NMDA/saline group at 28 days 
did not reach significance (p < 0.1) (B). Saline/Saline groups: n = 6, Saline/Ifenprodil groups: 
n = 8, NMDA/Saline groups: n = 10, NMDA/Ifenprodil groups: n = 10 animals. Error bars 
represent the standard error of the mean. * p < 0.05 v the relevant control (saline/saline or 
saline/ifenprodil) 
 
 
 
 
 
 
 
 
 
 
